Clinical Trial Update: SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating SFRT plus tislelizumab and platinum-based chemotherapy for unresectable stage III non-small cell lung cancer is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Platinum-based chemotherapy (platinum-based chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING